ANIP - Company ID 0001023024
The table below shows ANI PHARMACEUTICALS INC's balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $311.18M | $262.61M | $217.80M | $149.80M | $144.98M | $240.11M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | $255.43M | $252.62M | $225.65M | $220.33M | $196.36M | $166.09M |
| Inventory | $143.47M | $146.47M | $138.31M | $137.41M | $148.04M | $125.45M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $747.08M |
| $698.40M |
| $602.63M |
| $536.29M |
| $521.30M |
| $555.46M |
| Property, plant & equipment | $67.11M | $63.56M | $59.25M | $58.18M | $56.70M | $51.64M |
| Goodwill | $62.48M | $62.48M | $60.53M | $60.66M | $60.43M | $28.22M |
| Total assets | $1.42B | $1.41B | $1.34B | $1.29B | $1.29B | $920.75M |
| Accounts payable | $69.69M | $69.80M | $54.57M | $53.06M | $60.89M | $48.68M |
| Total current liabilities | $239.51M | $270.56M | $236.84M | $201.81M | $189.93M | $139.98M |
| Long-term debt | $286.00M | $297.68M | $301.48M | $305.29M | $312.92M | $284.39M |
| Total liabilities | $859.67M | $902.34M | $881.39M | $848.96M | $856.58M | $440.14M |
| Retained earnings | $6.39M | -$50.59M | -$76.86M | -$85.00M | -$89.60M | -$65.03M |
| Total equity | $562.30M | $505.82M | $436.76M | $418.62M | $405.95M | $455.76M |